Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease

Ankita  Basak; Soumyadip  Ghosh; Debgopal  Ganguly; Soukat  Garain; Riya Ghosh; Ananta  Choudhury; Himangshu  Deka; Jahnabi  Sarmah

doi:10.18231/j.joapr.2023.11.4.1.9

Authors

Ankita Basak Department of Pharmaceutics, Bengal School of Technology, Delhi Rd, Chinsurah RS, Sugandha, West Bengal 712102
Soumyadip Ghosh Department of Pharmaceutics, Bengal School of Technology, Delhi Rd, Chinsurah RS, Sugandha, West Bengal 712102
Debgopal Ganguly NSMS Institute of Pharmacy, Nachan Road, Kamalpur, Durgapur, Paschim Bardhaman,West Bengal
Soukat Garain School of Pharmacy, Seacom Skills University, Near Santiniketan, Kendradangal, Kendangal, West Bengal 731236
Riya Ghosh School of Pharmacy, Seacom Skills University, Near Santiniketan, Kendradangal, Kendangal, West Bengal 731236
Ananta Choudhury Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, Assam
Himangshu Deka NEPEDS College of Pharmaceutical Sciences, Tetelia, Kamrup(M), Assam
Jahnabi Sarmah NEPEDS College of Pharmaceutical Sciences, Tetelia, Kamrup(M), Assam

DOI:

https://doi.org/10.18231/j.joapr.2023.11.4.1.9

Keywords:

Nanoparticles, polymers, colon disease, IBD, Pathogenesis, Conventional treatment

Abstract

Targeting the drug delivery system is very tough nowadays due to premature drug release at the upper GIT tract and altered pH conditions. Colon-specific drug delivery systems can overcome that problem using different polymer combinations. A nanoparticulate drug delivery system is the prominent dosage form that impacts the bioavailability and requires a low dose to excrete the therapeutic efficacy. All nanoscience and nanotechnology are applications of Nanometrology, the science of measurements at the nanoscale. NPDDSs were primarily developed to combine the colloidal stability of solid particle suspensions in biological fluids and the solubilizing properties of liquids. An ideal drug-delivery system possesses two elements: the ability to target and control the drug release. Colloidal drug carriers offer a number of potential advantages as delivery systems, such as better bioavailability for poorly soluble drugs. Researchers have created various sophisticated and multifunctional nanocarrier systems that can transport pharmaceuticals in a targeted, sustained, and regulated manner to provide therapeutic medications that are safer and more effective, particularly to ulcerative colitis. These innovative technologies are improving the pharmacokinetic profile of pharmaceuticals, increasing their systemic circulation, and decreasing the frequency of pharmacological side effects. The review focuses on the current trend and future perspectives of natural polymer-based-loaded nanoparticle-based drug delivery systems for the management of inflammatory bowel disease.

Downloads

Download data is not yet available.

References

Lima IB, Moreno LC, Silva-Filho EC, Irache JM, Veiga FJ, Rolim HM, Nunes LC. Development of nanostructured systems using natural polymers to optimize the treatment of inflammatory bowel diseases: A prospective study. Journal of Drug Delivery Science and Technology 1(64), 102590 (2021).

Verma P, Srivastava A, Srikanth CV, Bajaj A. Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease. Biomaterials science 9(5),1481-502 (2021).

Shah BM, Palakurthi SS, Khare T, Khare S, Palakurthi S. Natural proteins and polysaccharides in the development of micro/nano delivery systems for the treatment of inflammatory bowel disease. International journal of biological macromolecules 15(165),722-37 (2020)

Collaborators GBDIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5 (1), 17–30 (2020).

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18, 56-66 (2021)

Abdulla M, Mohammed N, AlQamish J, Mosli M. Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis. Scientific Reports 12(1), 21333 (2022).

Barani M, Rahdar A, Sargazi S, Amiri MS, Sharma PK, Bhalla N. Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment. Sensing and bio-sensing research 1(32), 100417 (2021).

Patel A, Bhatt N, Patel KR, Patel NM, Patel MR. Colon targeted drug delivery system: a review system. J. Pharm. Sci. Biosci. Res. 1(1), 37–49 (2011).

Khare T, Palakurthi SS, Shah BM, Palakurthi S, Khare S. Natural product-based nanomedicine in treatment of inflammatory bowel disease. International Journal of Molecular Sciences 21(11), 3956 (2020).

Lai K, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev 61(2), 158-171 (2009).

Yang C, Merlin D. Can naturally occurring nanoparticle-based targeted drug delivery effectively treat inflammatory bowel disease? Expert Opin Drug Deliv 17 (1), 1–4 (2020).

Mowat AMI, Bain CC. Mucosal Macrophages in Intestinal Homeostasis and Inflammation. J. Innate Immun 3, 550–564 (2011).

Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research 28(48), 96-107 (2014).

Thorkildsen LT, Nwosu FC, Avershina E, Ricanek P, Perminow G, Brackmann S, et al. Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients. Gastroenterol Res Pract 636785 (2013).

Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticoid steroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (106), 590-599 (2011)

Gisbert JP, Nino P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394patients. Aliment Pharmacol Ther (28), 228-238 (2008).

Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 29(6), 654-661 (2009).

Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest, (92), 2675-2682 (1993).

Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol (305), G763-G785 (2013).

Yamanishi H, Murakami H, Ikeda Y, Abe M, Kumagi T, HiasaY, et al. Regulatory dendritic cells pulsed with carbonic anhydride protect mice from colitis induced by CD4+. J Immunol 188, 2164-2172 (2012).

Godoi DF, Cardoso CR, Ferraz D B, Provinciatto PR, Cunha FQ, Silva JS, etal. Hematopoietic SCT modulates gut inflammation in experimental inflammatory bowel disease. Bone Marrow Transplant 45, 1562-1571 (2010).

Ghannam S, Pene J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit humanTh17cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185, 302-312 (2010).

Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert opinion on drug delivery 9(11),1393-407 (2012).

Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical Research 18, 788-93 (2001).

Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. Journal of Pharmaceutical Sciences 90(12), 1927-36 (2001).

Tomalia DA, Khanna SN. A systematic framework and nanoperiodic concept for unifying nanoscience: hard/soft nanoelements, superatoms, meta-atoms, new emerging properties, periodic property patterns, and predictive Mendeleev-like nanoperiodic tables. Chem Rev 116, 2705–74 (2016).

Naha PC, Hsu JC, Kim J, Shah S, Bouché M, Si-Mohamed S, Rosario-Berrios DN, Douek P, Hajfathalian M, Yasini P, Singh S. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. ACS nano 14(8), 10187-97 (2020)

Dhand C, Dwivedi N, Loh XJ, Ying AN, Verma NK, Beuerman RW, Lakshminarayanan R, Ramakrishna S. Methods and strategies for the synthesis of diverse nanoparticles and their applications: a comprehensive overview. RSC Advances 5(127), 105003-105037 (2015)

Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release 161(2), 505-22 (2012)

Sánchez-López E, Gomes D, Esteruelas G, Bonilla L, Lopez-Machado AL, Galindo R, et al. Metal-based nanoparticles as antimicrobial agents: an overview. Nanomaterials 10(2), 292 (2020)

You X, Kang Y, Hollett G, Chen X, Zhao W, Gu Z, Wu J. Polymeric nanoparticles for colon cancer therapy: overview and perspectives. Journal of Materials Chemistry B 4(48), 7779-7792 (2016)

Ajitkumar BN, Kumar L. Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systems. Journal of Controlled Release 336, 16-39 (2021)

Mohammed MA, Syeda J, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and their application in non-parenteral drug delivery. Pharmaceutics 9(4), 53-57 (2017)

Ghosh S, Majumdar S, Ganguly D. A brief review on colon-specific drug delivery system for targeting to colonic region. Journal of Applied Pharmaceutical Research 9(4), 9–15 (2021).